Premium
Efficacy and tolerance of GELOXD /P‐ GEMOXD in newly diagnosed nasal‐type extranodal NK /T‐cell lymphoma: A multicenter retrospective study
Author(s) -
Li JiWei,
Li YaJun,
Zhong MeiZuo,
Liu XianLing,
Li Jin,
Li KunLun,
Liu XiYu,
Zhou Fang,
OuYang Zhou,
Sun ZhongYi,
Huang LiJun,
He JunQiao,
Zhou Hui,
Yi PingYong
Publication year - 2018
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.13004
Subject(s) - medicine , gastroenterology , lymphoma , regimen , leukopenia , nausea , vomiting , chemotherapy , t cell lymphoma , proportional hazards model , stage (stratigraphy) , oncology , surgery , paleontology , biology
Objectives Nasal‐type extranodal natural killer NK /T‐cell lymphoma ( ENKTCL ) i s a distinct type of non‐Hodgkin lymphoma with poor prognosis. This research aimed to evaluate the efficacy and safety of the GELOXD or P‐ GEMOXD regimens in patients with ENKTCL . Methods Newly diagnosed ENKTCL patients treated with either the GELOXD or the P‐ GEMOXD regimen were identified from three cancer centers between January 2010 and December 2016. Kaplan‐Meier and Cox regression analyses were used to calculate overall survival ( OS ) and progression‐free survival ( PFS ) and to investigate prognostic factors. Results One hundred and eighty‐four cases were identified from three cancer centers. After 1‐5 treatment cycles of GELOXD or P‐ GEMOXD chemotherapy, 155 (84%) patients showed a complete response ( CR ). The 3‐year OS (73.0% vs 38.2%, P = .001) and PFS (72.8% vs 32.4%, P = .000) rates were significantly higher in early‐stage patients compared with advanced‐stage patients. A multivariate analysis revealed that patient CR status was a significant independent factor in disease prognosis. Grade 3/4 leukopenia occurred in 43 (23.4%) patients. Major non‐hematological toxicities included nausea (n = 117, 63.6%) and vomiting (n = 66, 35.9%). Conclusions The GELOXD and P‐ GEMOXD chemotherapy regimens are well tolerated and provide favorable survival outcomes in patients with ENKTCL .